Business Wire

TRINITY Opens First European Office in Munich

Share

TRINITY, a strategic partner to leading life sciences companies, today officially opened its flagship European office in Munich, Germany. The 20-year-old firm, with over 250 professionals working with more than 100 biopharmaceutical and medical device clients annually, will now serve clients from a dedicated European office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190630005029/en/

Alexander B. Fink, Managing Partner Europe, TRINITY (Photo: Business Wire)

Alexander B. Fink, Managing Partner Europe, TRINITY (Photo: Business Wire)

“We are very excited to open this new chapter for TRINITY, and we look forward to serving our European clients directly from our European office,” said David Fitzhenry, TRINITY CEO.

Alexander Fink, Managing Partner Europe, will head TRINITY’s operations in Europe and will oversee strategy and direction in the European markets. Jackson Carroll, Principal, joins his leadership team and will be supported by a team combining European experience both at TRINITY and from other top-tier strategic advisory firms. The European team will be positioned to develop evidence-based solutions for life sciences companies in Europe, leveraging European experience and seamlessly integrating TRINITY’s global knowledge and tools.

“We are pleased to be joining TRINITY, a firm that puts client needs first and brings deep biopharmaceutical experience across our three pillars: advisory services, insights & analytics, and technology,” said Fink.

Over the course of his 20-plus years in management consulting, Fink has advised more than 70 clients in over 300 strategic assignments. He joins from Syneos Health, where he built the European commercial strategy consulting business, and recently headed the global Product & Franchise Strategy service line as Senior Managing Director. Prior to Syneos Health, Fink spent a number of years in senior positions in top-tier consulting firms, such as Oliver Wyman and Monitor. Fink studied business administration in Germany, UK and the US.

Jackson Carroll brings over 17 years of experience in management consulting to TRINITY. He also joins from Syneos Health where he was a Senior Engagement Manager in its Commercial Advisory Group. Prior to that Carroll worked at global strategy consulting firms ZS Associates and McKinsey & Company. He earned an MBA with distinction from London Business School.

About TRINITY
TRINITY
is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, TRINITY is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights.

TRINITY’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS. TRINITY, together with its subsidiary TGaS® Advisors, has 5 offices throughout the US, including Boston, New York, Princeton, Philadelphia, and San Francisco as well as Toronto, Canada, and Gurgaon, India. In July 2019, TRINITY opened its first European Office in Widenmayerstr. 50, 80538 Munich, Germany. To learn more about how TRINITY is elevating life sciences and driving from evidence to action, visit trinitylifesciences.com

For media and general inquiries, contact Kirsten Brady, SVP Commercial, TRINITY. kbrady@trinitylifesciences.com; 973-223-6089

Contact information

Alexander B. Fink
Managing Partner Europe, TRINITY
afink@trinitylifesciences.com
+49 170 7869901

Jackson Carroll
Principal Europe, TRINITY
jcarroll@trinitylifesciences.com
+49 170 7869902

Kirsten Brady
SVP Commercial, TRINITY
kbrady@trinitylifesciences.com
+ 1 973-223-6089

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 01:30:00 CESTPress release

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an

IBC Celebrates Young Talent in the Industry22.7.2019 15:36:00 CESTPress release

The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current

Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 13:42:00 CESTPress release

Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e